Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
TRex Bio
AddedFeb 17, 2024
UpdatedJun 18, 2026
TRex Bio

TRex Bio

Series A

TRexBio: A biotech firm innovating cancer and inflammatory disease therapeutics using advanced computational biology.

HQ
South San Francisco, CA, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

TRexBio, founded with a mission to revolutionize therapeutics for cancer and inflammatory diseases, leverages advanced computational biology and a deep understanding of human tissue. The company’s core vision is to decode human tissue biology to create groundbreaking treatments. Their primary product is the Deep Biology Platform, which maps regulatory T cell behavior in human tissues to disease dysregulation, enabling the identification of novel therapeutic targets. TRexBio focuses on immune-mediated diseases, aiming to bring transformative solutions to the healthcare market.

Notable figures associated with TRexBio include leading experts in immunobiology and computational biology, though specific names are not provided. The company has attracted significant interest from investors in the biotech sector, reflecting confidence in its innovative approach. Key achievements include the development and application of their proprietary Deep Biology Platform, which has shown promise in identifying new therapeutic targets. TRexBio’s impact lies in its potential to introduce highly effective treatments for complex diseases, thereby improving patient outcomes and advancing medical science.

TRex Bio - Similar Companies

Tr1x logo

Tr1x

tr1x.bio

GentiBio logo

GentiBio

gentibio.com

3T Biosciences logo

3T Biosciences

3tbiosciences.com

Alltrna logo

Alltrna

alltrna.com

Treeline Biosciences logo

Treeline Biosciences

Sonoma Biotherapeutics logo

Sonoma Biotherapeutics

Therini Bio logo

Therini Bio

therinibio.com

HI-Bio logo

HI-Bio

hibio.com

Tract Therapeutics logo

Tract Therapeutics

TenSixty Biosciences logo

TenSixty Biosciences

tensixty.bio

Trellis Bioscience logo

Trellis Bioscience

trellisbio.com

Trestle Biotherapeutics logo

Trestle Biotherapeutics

trestlebio.com

Regenerative Bio logo

Regenerative Bio

regen-bio.us

Fauna Bio logo

Fauna Bio

faunabio.com

Aibios logo

Aibios

aibios.com

TRex Bio - Quick Facts

Who are TRex Bio's competitors?

Companies similar to TRex Bio include Tr1x, GentiBio, 3T Biosciences and Alltrna.

When was TRex Bio founded?

TRex Bio was founded in 2018.

Where is TRex Bio's headquarters located?

TRex Bio's headquarters is located in South San Francisco, CA, US.

When was TRex Bio's last funding round?

TRex Bio's most recent funding round was for $26M (USD) in March 2022.

How much has TRex Bio raised to-date?

As of Mar 8, 2022, TRex Bio has raised a total of $85M (USD).

How many employees does TRex Bio have?

TRex Bio has 69 employees as of Feb 4, 2024.

TRex Bio - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Therapeutics
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software